Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 5/20 | 0.64 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.64 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | TYR | P14679 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 4/20 | 0.51 |
| ▸ | HKDC1 | Q2TB90 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | TNNI3 | P19429 | 2/20 | 0.51 |
| ▸ | TNNT2 | P45379 | 2/20 | 0.51 |
| ▸ | TNNC1 | P63316 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14164007 | 1.00 | SLC5A2 (0.64) | SLC5A2SLC5A1SLC28A3ATMTYR | |
| SCHEMBL244406 | 1.00 | SLC5A2 (0.64) | SLC5A2SLC5A1SLC28A3ATMTYR | |
| SCHEMBL8654092 | 1.00 | SLC5A2 (0.64) | SLC5A2SLC5A1SLC28A3ATMTYR | |
| SCHEMBL29382560 | 1.00 | SLC5A2 (0.64) | SLC5A2SLC5A1SLC28A3ATMTYR | |
| SCHEMBL28176940 | 1.00 | SLC5A2 (0.64) | SLC5A2SLC5A1SLC28A3ATMTYR | |
| SCHEMBL8659653 | 1.00 | SLC5A2 (0.64) | SLC5A2SLC5A1SLC28A3ATMTYR | |
| SCHEMBL8654543 | 1.00 | SLC5A2 (0.64) | SLC5A2SLC5A1SLC28A3ATMTYR | |
| SCHEMBL7039100 | 0.90 | SLC5A2 (0.56) | SLC5A2SLC5A1SLC28A3ATMTYR | |
| SCHEMBL1599039 | 0.90 | SLC5A2 (0.56) | SLC5A2SLC5A1SLC28A3ATMTYR | |
| SCHEMBL941002 | 0.88 | SLC28A3 (0.62) | SLC5A2SLC5A1SLC28A3TYRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1727354-A | Compound in category of trioside methyl salicylate, oside ester saccharide | DING YI (CN) | 2006-02-01 | — | — | CN | claimed |
| CN-118048365-B | ZmSKI3 gene related to disease resistance of corn and application thereof | 河南农业大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20250351855-A1 | TASTE OF CONSUMABLES | THE PRODUCT MAKERS (AUSTRALIA) PTY LTD (AU) | 2025-11-20 | — | — | US | disclosed |
| US-12370232-B2 | Use of polyphenol containing sugar cane extracts for preventing, improving or treating a skin condition | Poly Gain Pte Ltd (SG) | 2025-07-29 | — | — | US | disclosed |
| CN-120209052-A | Method for separating salicylic acid 2-O-beta-D-glucoside from biological fermentation liquid | 中国科学院天津工业生物技术研究所 | 2025-06-27 | — | — | CN | disclosed |
| CN-120209052-A | Method for separating salicylic acid 2-O-beta-D-glucoside from biological fermentation liquid | 中国科学院天津工业生物技术研究所 | 2025-06-27 | — | — | CN | disclosed |
| CN-118048365-A | ZmSKI3 gene related to disease resistance of corn and application thereof | 河南农业大学 | 2024-05-17 | — | — | CN | disclosed |
| US-20230173012-A1 | USE OF POLYPHENOL CONTAINING SUGAR CANE EXTRACTS FOR PREVENTING, IMPROVING OR TREATING A SKIN CONDITION | THE PRODUCT MAKERS (AUSTRALIA) PTY LTD (AU) | 2023-06-08 | — | — | US | disclosed |
| US-20230157342-A1 | TASTE OF CONSUMABLES | THE PRODUCT MAKERS (AUSTRALIA) PTY LTD (AU) | 2023-05-25 | — | — | US | disclosed |
| CN-113249395-B | Application of soybean agglutinin receptor kinase Rsc7-1 coding gene | 南京农业大学 | 2022-04-29 | — | — | CN | disclosed |
| US-20180043497-A1 | Polishing Agent, Stock Solution for Polishing Agent, and Polishing Method | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| US-20170368080-A1 | METHODS FOR TREATING TAUOPATHY | THE J. DAVID GLADSTONE INSTITUTES | 2017-12-28 | — | — | US | disclosed |
| EP-3244914-A1 | METHODS FOR TREATING TAUOPATHY | The J. David Gladstone Institutes (US) | 2017-11-22 | — | — | EP | disclosed |
| WO-2016115520-A1 | METHODS FOR TREATING TAUOPATHY | THE J. DAVID GLADSTONE INSTITUTES (US) | 2016-07-21 | — | — | WO | disclosed |
| US-20090106858-A1 | Isolation and Characterization of the Csb3-1 Mutant of Arabidopsis Thaliana and Use Thereof as a Regulator of Resistance in Plants to Diseases Caused by Biotrophic Pathogens | UNIVERSIDAD POLITECNICA DE VALENCIA (ES) | 2009-04-23 | — | — | US | disclosed |
| EP-1908838-A2 | ISOLATION AND CHARACTERISATION OF THE CSB3-1 MUTANT OF ARABIDOPSIS THALIANA AND USE THEREOF AS A REGULATOR OF RESISTANCE IN PLANTS TO DISEASES CAUSED BY BIOTROPHIC PATHOGENS | Consejo Superior de Investigaciones Cientificas (ES) | 2008-04-09 | — | — | EP | disclosed |
| EP-1649029-A1 | A METHOD OF PRODUCING A LOW MOLECULAR WEIGHT ORGANIC COMPOUND IN A CELL | Poalis A/S (DK) | 2006-04-26 | — | — | EP | disclosed |
| CN-1727354-A | Compound in category of trioside methyl salicylate, oside ester saccharide | DING YI (CN) | 2006-02-01 | — | — | CN | disclosed |
| WO-2005038004-A2 | METHOD TO PRODUCT PARA-HYDROXYBENZOIC ACID IN THE STEM TISSUE OF GREEN PLANTS BY USING A TISSUE-SPECIFIC PROMTER | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2004111254-A1 | A METHOD OF PRODUCING A LOW MOLECULAR WEIGHT ORGANIC COMPOUND IN A CELL | POALIS A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368080-A1 | METHODS FOR TREATING TAUOPATHY | MAPT, PYGB, CHAT | SLC5A2 923/4885SLC5A1 645/4885SLC28A3 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.